Maureen Beresini
Overview
Explore the profile of Maureen Beresini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gurung H, Heidersbach A, Darwish M, Chan P, Li J, Beresini M, et al.
Nat Biotechnol
. 2023 Oct;
42(7):1107-1117.
PMID: 37857725
The broad application of precision cancer immunotherapies is limited by the number of validated neoepitopes that are common among patients or tumor types. To expand the known repertoire of shared...
2.
Tran J, Hunsaker T, Bell C, Ma T, Chan E, Saenz-Lopez Larrocha P, et al.
Anal Chem
. 2023 Mar;
95(11):4834-4839.
PMID: 36876898
The growing opportunities recognized for covalent drug inhibitors, like KRAS G12C inhibitors, are driving the need for mass spectrometry methods that can quickly and robustly measure therapeutic drug activity for...
3.
Beveridge R, Wallweber H, Ashkenazi A, Beresini M, Clark K, Gibbons P, et al.
ACS Med Chem Lett
. 2020 Dec;
11(12):2389-2396.
PMID: 33335661
Amino-quinazoline BRaf kinase inhibitor was identified from a library screen as a modest inhibitor of the unfolded protein response (UPR) regulating potential anticancer target IRE1α. A combination of crystallographic and...
4.
Castanedo G, Blaquiere N, Beresini M, Bravo B, Brightbill H, Chen J, et al.
J Med Chem
. 2016 Dec;
60(2):627-640.
PMID: 28005357
We report here structure-guided optimization of a novel series of NF-κB inducing kinase (NIK) inhibitors. Starting from a modestly potent, low molecular weight lead, activity was improved by designing a...
5.
Bergeron P, Koehler M, Blackwood E, Bowman K, Clark K, Firestein R, et al.
ACS Med Chem Lett
. 2016 Jun;
7(6):595-600.
PMID: 27326333
Using Sorafenib as a starting point, a series of potent and selective inhibitors of CDK8 was developed. When cocrystallized with CDK8 and cyclin C, these compounds exhibit a Type-II (DMG-out)...
6.
Liang J, Tsui V, Van Abbema A, Bao L, Barrett K, Beresini M, et al.
Eur J Med Chem
. 2013 Jul;
67:175-87.
PMID: 23867602
A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as psoriasis and inflammatory bowel diseases (IBD), by selective targeting of TYK2. Hit triage, following a high-throughput screen...
7.
Flygare J, Beresini M, Budha N, Chan H, Chan I, Cheeti S, et al.
J Med Chem
. 2012 Mar;
55(9):4101-13.
PMID: 22413863
A series of compounds were designed and synthesized as antagonists of cIAP1/2, ML-IAP, and XIAP based on the N-terminus, AVPI, of mature Smac. Compound 1 (GDC-0152) has the best profile...
8.
Lu Y, Vernes J, Chiang N, Ou Q, Ding J, Adams C, et al.
J Immunol Methods
. 2010 Dec;
365(1-2):132-41.
PMID: 21185301
Clinical response to the anti-CD20 antibody rituximab has been demonstrated to correlate with the polymorphism in the FcγRIIIa receptor where patients homozygous for the higher affinity V158 allotype showed a...
9.
Olivero A, Eigenbrot C, Goldsmith R, Robarge K, Artis D, Flygare J, et al.
J Biol Chem
. 2005 Jan;
280(10):9160-9.
PMID: 15632123
The serine protease factor VIIa (FVIIa) in complex with its cellular cofactor tissue factor (TF) initiates the blood coagulation reactions. TF.FVIIa is also implicated in thrombosis-related disorders and constitutes an...
10.
Burdick D, Marsters Jr J, Aliagas-Martin I, Stanley M, Beresini M, Clark K, et al.
Bioorg Med Chem Lett
. 2004 Apr;
14(9):2055-9.
PMID: 15080978
o-Bromobenzoyl l-tryptophan 1 inhibits the association of LFA-1 with ICAM-1 with an IC(50) of 1.7microM. Evaluation of the structure-activity relationship of the benzoyl moiety shows that 2,6-di-substitutions greatly enhance potency...